Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia
Les mutations oncogénétiques associées à la MRD améliorent la prédiction du risque de rechute des leucémies aiguës lymphoblastiques T pédiatriques
Abstract
Key Points In pediatric T-ALL, oncogenetic markers, MRD, and WBC count are independent predictors of outcome. These factors should be used together for individual treatment stratification.